T1	Participants 191 252	intravenous drug users (IVDUs) with chronic hepatitis C (CHC)
T2	Participants 593 656	406 previously untreated CHC patients, including 98 (24%) IVDUs
T3	Participants 1676 1689	IVDU patients
